

Today's issue of PD

Pharmacy Daily today comprises three pages of news, including our **Beauty & Wellness** feature.

Sainsbury awards nominations open

THE Australian Pharmacy Council (APC) is inviting applications for the 2026 Dr Erica Sainsbury Awards, recognising leaders in pharmacy education and practice who have demonstrated a commitment to investing in the pharmacists of the future.

An academic at the University of Sydney, Dr Sainsbury dedicated more than 30 years to pharmacy education, and passed away in Dec 2021 having left a lasting mark on the profession.

APC created two award categories to honour her legacy as both a passionate academic and collaborator.

The Early Career Pharmacy Educator Award recognises an individual who demonstrates innovation and passion in teaching and places students first and foremost.

The Pharmacist Supervisor Award, open by nomination only, recognises pharmacists who display the attributes and skills considered invaluable in the training of pharmacy interns and other workplace-based learners.

Submissions for the Dr Erica Sainsbury Awards close Mon 31 Aug 2026, with winners named at the APC's Emeritus Professor Lloyd Sansom AO Distinguished Lecture series in Nov - learn more [HERE](#).

Ethics code reflects profession's evolution

THE Pharmaceutical Society of Australia has launched the new Code of Ethics for pharmacists, articulating the values of the pharmacy profession and expected ethical standards.

Underpinning the professional practice of all Australian pharmacists, the Code of Ethics applies to all pharmacists and pharmacy students registered with the Pharmacy Board of Australia.

The new Code is the result of 12 months of development and collaboration, and reflects the expanding roles of pharmacists as well as broader societal changes.

Built around four domains - care, integrity, competency and collaboration - it acknowledges the increasingly complex healthcare landscape, including prescribing and vaccination services, growth in digital health, expanded scope of practice, and growing patient needs.

Project Advisory Group chair Dr Ayomide Ogundipe said the revised Code of Ethics aims to support pharmacists better as they face increasingly complex ethical challenges due to role expansion as

well as broader societal changes.

"Ethics is not abstract - it shapes the decisions pharmacists make every day, from how we communicate with patients and manage conflicts of interest, to when we refer, how we support colleagues and how we respond when the practice environment challenges our ability to provide safe and effective care," explained Dr Ogundipe.

"With greater responsibility from the increasing breadth of scope of practice comes greater accountability," she continued.

"Pharmacists must be familiar with these ethical obligations as our role in the health system continues to grow," Dr Ogundipe said.

A welcome addition to the new Code is recognition of ethical obligations relating to practitioner wellbeing, with creating a supportive practice environment seen as an ethical responsibility.

Dr Ogundipe thanked the Project Advisory Group for their expertise, insight and commitment.

Pharmacists will have the opportunity to learn more about



the new Code of Ethics at a webinar being held on Thu 21 Jul, as well as sessions at PSA26.

Access the Code [HERE](#).

New drug listings for ALGS, haemophilia

IPSEN Australia has announced that Bylvay (odevixibat) is now approved to treat cholestatic pruritus associated with Alagille syndrome (ALGS), a rare genetic liver disease characterised by a relentless itch.

Already registered for progressive familial intrahepatic cholestasis (PFIC), Bylvay is the first medicine specifically approved in Australia for treating cholestatic pruritus in ALGS.

Ipsen is currently seeking a PBS listing for this indication.

MEANWHILE, the Therapeutic

Goods Administration (TGA) has approved the registration of ALTUVIIIIO (efanesoctocog alfa, Sanofi), a first-in-class, high-sustained factor VIII replacement therapy designed to provide extended protection against bleeding episodes in people with haemophilia A.

With a once-weekly dosing schedule, the new listing will free people living with haemophilia A from the need for multiple transfusions per week, addressing a key unmet need in the condition's treatment.

Vita-D Mini Tablets
Supports bone health, muscle strength and calcium absorption. **NEW**

Available in **90's and 250's**
Symbion, Sigma, API & CH2

Always read the label and follow directions for use.

MedView

Powering Modern Pharmacy

Worx

MedView Smart Shelf

Discover Smarter Pharmacy Solutions

medview.com.au



When you're building what's next for your pharmacy, we're here to back you.

Contact **Melissa Reader** for a confidential chat - PH: 0499 832 836 E: melissa.reader@ipagroup.com
ipagroup.com | PH: 1300 001 724



LEARN MORE

Editor's Choice: Real Techniques x Cloudtopia launch limited collection

MAYBELLINE and Real Techniques have collaborated to launch the new Cloudtopia collection of products.

The range of custom tools was designed to pair with the cosmetic giant's new Cloudtopia cheek and lip mousse (RRP \$24.99), an ultra-pigmented, soft-focus product with up to 14-hour wear and available in six shades.

Featured in the limited-edition range is the Real Techniques Cloudtopia Blush Brush (RRP \$29.99), a dual-ended brush created to use in conjunction with the mousse.

The small end of the brush can be used to place pigment, while the dense, sloped side can be used to buff and diffuse.



Also included in the collection is the Real Techniques Cloudtopia Touch Up Brush Set (RRP \$45.99), featuring five custom mini

brushes to diffuse powder and bronzer, as well as blur lip colour.

The range is available now in Priceline nationwide.

DB is all about lips



AUSTRALIAN affordable makeup brand DB Cosmetics has released this month its All About Lips collection of products, designed to plump, nourish and colour.

Featured in the range is the Lip Boost Plumping Treatment (RRP \$13.99) inspired by Too Faced Cosmetics; and the Pep Talk Lip Kit (RRP \$24.99), which includes a conditioning peptide lip tint and lip balm.

Also included is the three-piece Lavish Lip Gloss Kit (RRP \$19.99); and the Marshmallow Lips Set (RRP \$16.99), a two-set system that includes an overnight mask and lip balm to deeply condition and hydrate, plus a bonus lip charm.

Known as the top cosmetic brand in community pharmacy for the past decade according to Circana Scan Data, DB Cosmetics is also set to celebrate its 20th anniversary in September with a collection of products to mark the occasion.

Vichy collagen serum

VICHY'S new collagen peptide serum, called the Liftactiv Collagen Specialist 16 Bonding Serum 3, aims to develop plumper, firmer and more radiant skin.

The serum targets 16 signs of ageing, including wrinkles, fine lines and skin texture.



Lanolips releases Milkshake ceramide collection



AUSTRALIAN beauty brand Lanolips has just launched the Ceramide Milkshake Balm (RRP \$14.95), formulated with 90% ultra-pure lanoline with ceramides and murmuru butter.

Scented like a milkshake, the new balms aim to deeply moisturise, strengthen the lip barrier and deliver a sheer, glossy tint.

"Ceramides are having a moment right now, but for us it was never about the trend, it was about what those ingredients do together for the skin barrier," Lanolips founder Kirsten Carriol told *Retail Beauty*. "When something genuinely works, it doesn't go out of style - our customers know that better than anyone," she added.

Available now in four flavours including Strawberry Bubble, Raspberry Crumble, Caramel Melt and Mocha Choca.

The brand is now looking to further overseas expansion in the future, across the US, UK, Europe and the Middle East.

Want to feature on this page?

email advertising@pharmacydaily.com.au to find out more

Beauty & Wellness
by Pharmacy Daily



Dispensary Corner

WHILE people air concerns about AI taking their jobs, among the technology's benefits is that it could be making our children.

Doctors at the Columbia University Fertility Centre have successfully trialled its AI-powered Sperm Tracking and Recovery system (STAR), which identifies and isolates sperm, allowing couples to develop a healthy baby.

STAR uses high-powered imaging technology to scan through sperm samples, capturing over eight million images in under an hour.

The doctors then have a short window to retrieve the sperm and fertilise an egg with it.

The successful trial was done with a US couple who had long been trying to conceive.

Testing revealed that the man had Klinefelter's syndrome, with symptoms including smaller testicles and reduced fertility.

The doctors were able to retrieve eight sperm, and inject them into eight eggs, one of which successfully developed to blastocyst stage and could be implanted - and the couple are now expecting a child.

Fertility clinics have been using AI for their general day-to-day operations such as choosing embryos at the lowest risk of developing illnesses, and screening fetuses to gauge characteristics like height, weight and smarts.

Fertility specialists told the *New York Post* that they don't expect AI to replace them.

Patients face pricing policy pinch

DRUG pricing policies are starting to bite in Australia, with some further impending withdrawals from the Pharmaceutical Benefits Scheme (PBS) expected to have significant impacts on patients.

Indivior has announced the discontinuation of its long-acting buprenorphine injection Sublocade from Australia at the end of Dec 2026, citing operational and commercial considerations.

"The change in availability of Sublocade will reduce patient choice," addiction medicine pharmacist Professor Suzanne Nielsen told *Pharmacy Daily*.

"For some patients, these long-acting injectable buprenorphine products are not directly interchangeable, as they have different pharmacokinetic profiles that can lead to different clinical effect," she explained.

"With Sublocade becoming unavailable, pharmacists will play a key role in supporting safe transitions, reinforcing continuity of care, and helping patients understand any changes to their treatment," she added.

While not explicitly stated by the company, addiction medicine specialist Professor John Saunders told *Australian Doctor* that he understood Indivior's decision "reflected dissatisfaction with PBS prices".

MEANWHILE, advocates have raised the alarm as two drugs for treating multiple sclerosis are at risk of being pulled from the PBS as a consequence of government-driven policy-related price reductions.

The drugs - Ocrevus (ocrelizumab, Roche) and Kesimpta (ofatumumab, Novartis) - are both high-efficacy MS therapies that are used first-line for many patients, helping people with the condition live longer and



healthier lives, while also helping to reduce the burden on Australia's healthcare system.

The government has reportedly requested Novartis and Roche cut the price of the medicines by 40%, in line with a cheaper comparator medicine recently added to the PBS.

"If this government decision goes ahead, people with MS will be limited in the choice of available treatments they can access affordably through the PBS," MS Australia acting CEO Dr Julia Morahan said.

"We urge the government to work with the relevant stakeholders and the MS community to ensure continued access to high-efficacy MS medications on the PBS," she added. *KB*

Sleep apnoea dementia link

A MONASH University study has linked untreated obstructive sleep apnoea (OSA) with poor memory and dementia risk factors.

The study included over 2,700 participants aged 40-70 years, who completed online assessments of thinking skills and health.

Researchers noted poorer memory was mainly found among people with untreated OSA, while those receiving treatment performed similarly to people without the condition.

There was also a link between OSA and modifiable dementia risk factors, including obesity, high blood pressure and high cholesterol.

Lead author Gabriel Abdelmessih said the findings emphasise the importance of identifying and managing sleep apnoea early in life, well before any significant cognitive decline becomes apparent.

Read the paper [HERE](#).

NIP pneumococcal changes now in effect

THE Australian Immunisation Handbook has been updated to reflect expanded adult pneumococcal eligibility under the National Immunisation Program (*PD* 26 Jun).

Among the changes is a newly listed vaccine, Capvaxine (21vPCV, MSD), which has replaced 13vPCV as the NIP-funded vaccine for adults aged over 18 years.

Other changes include the lowering of the recommended age for Aboriginal and Torres Strait Islander adults from 50 years to 25 years and older, and

the lowering of the recommended age for all other adults without risk conditions from 70 years to 65 years and older.

Preventative health advocate, Dr Sarah Chu, said the changes may help protect eligible adults against pneumococcal disease.

"The expansion of the adult pneumococcal NIP has been long awaited, as pneumococcal disease and invasive pneumococcal disease in particular, may lead to severe illness, long-term consequences and even death," Dr Chu said.

See the updates [HERE](#).